How to Make Amphetamine Tablets Last Longer in Your Body
This patent describes a specific type of extended-release amphetamine tablet that combines different forms of amphetamine and special coatings to provide a therapeutic effect for at least thirteen hours after a single dose.
Original patent title: “Extended release amphetamine tablets”
This patent describes a specific type of extended-release amphetamine tablet that combines different forms of amphetamine and special coatings to provide a therapeutic effect for at least thirteen hours after a single dose. Granted in 2026.
Coverage
What does this patent actually cover?
This patent describes an oral amphetamine tablet designed to release its active ingredient over a long period. The tablet uses a combination of three main components, as detailed in the abstractabstractA short summary at the front of the patent describing the invention. Not legally binding.Read more →: an uncoated amphetamine-cation exchange resin complex, a barrier-coated amphetamine-cation exchange resin complex-matrix, and some uncomplexed amphetamine. One or more of these components can include blends of different forms of amphetamines. This specific design ensures that a helpful amount of amphetamine is available in the body within about one hour and continues to work for at least thirteen hours after taking the pill. For example, a person taking this tablet once in the morning would experience the drug's effects throughout the entire day.
The gap
What does this patent NOT cover?
- Does not cover immediate-release amphetamine tablets that release all their active ingredient quickly.
- Does not cover extended-release formulations that achieve their effect solely through a single type of coated amphetamine complex.
- Does not cover extended-release mechanisms that do not involve a cation exchange resin complex.
- Does not cover formulations that lack either the uncoated complex, the barrier-coated complex-matrix, or the uncomplexed amphetamine component.
- Does not cover other types of drugs, only amphetamine compositions.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever part is combining multiple distinct amphetamine components—uncoated complex, barrier-coated complex-matrix, and uncomplexed amphetamine—potentially with different amphetamine forms, to precisely control the drug's release. This allows for both a quick initial effect and a sustained release over many hours from a single tablet.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Adderall XR
Vyvanse
Concerta (for methylphenidate, but similar extended-release principle)
Most modern extended-release ADHD medications
Why it matters
The bigger picture
Extended-release amphetamine formulations are crucial for treating conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. They allow patients to take a single dose daily, maintaining steady drug levels and improving adherence to treatment. This approach avoids the need for multiple doses throughout the day, which can be inconvenient and lead to missed doses.
Filed
March 20, 2026
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Major pharmaceutical companies like Takeda Pharmaceutical Company (makers of Vyvanse) and Teva Pharmaceutical Industries (makers of generic Adderall XR) are continuously developing and refining extended-release formulations for central nervous system stimulants. Other companies like Johnson & Johnson and Eli Lilly also have significant interests in this therapeutic area.
Market impact
The development of extended-release formulations significantly transformed the market for ADHD and narcolepsy treatments. These formulations offered improved patient convenience and compliance, leading to their widespread adoption and often commanding premium pricing over immediate-release versions. This patent contributes to the ongoing innovation in drug delivery, aiming to provide even more precise and long-lasting therapeutic effects.
Claim 1 — Plain English
What this patent covers
This patent describes an oral amphetamine tablet designed to release its active ingredient over a long period. The tablet uses a combination of three main components, as detailed in the abstract: an uncoated amphetamine-cation exchange resin complex, a barrier-coated amphetamine-cation exchange resin complex-matrix, and some uncomplexed amphetamine. One or more of these components can include blends of different forms of amphetamines. This specific design ensures that a helpful amount of amphetamine is available in the body within about one hour and continues to work for at least thirteen hours after taking the pill. For example, a person taking this tablet once in the morning would experience the drug's effects throughout the entire day.
The clever bit
The clever part is combining multiple distinct amphetamine components—uncoated complex, barrier-coated complex-matrix, and uncomplexed amphetamine—potentially with different amphetamine forms, to precisely control the drug's release. This allows for both a quick initial effect and a sustained release over many hours from a single tablet.
What it does not cover
- Does not cover immediate-release amphetamine tablets that release all their active ingredient quickly.
- Does not cover extended-release formulations that achieve their effect solely through a single type of coated amphetamine complex.
- Does not cover extended-release mechanisms that do not involve a cation exchange resin complex.
- Does not cover formulations that lack either the uncoated complex, the barrier-coated complex-matrix, or the uncomplexed amphetamine component.
- Does not cover other types of drugs, only amphetamine compositions.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 19.4 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). How to Make Amphetamine Tablets Last Longer in Your Body (U.S. Patent No. 12,734,132). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12734132/extended-release-amphetamine-tablets
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12734132"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does How to Make Amphetamine Tablets Last Longer in Your Body cover?
This patent describes a specific type of extended-release amphetamine tablet that combines different forms of amphetamine and special coatings to provide a therapeutic effect for at least thirteen hours after a single dose.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
Extended-release amphetamine formulations are crucial for treating conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. They allow patients to take a single dose daily, maintaining steady drug levels and improving adherence to treatment. This approach avoids the need for multiple doses throughout the day, which can be inconvenient and lead to missed doses.
What does this patent NOT cover?
Does not cover immediate-release amphetamine tablets that release all their active ingredient quickly.
Patent monitoring